This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
Aytu Bioscience, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of 61.54% and 16.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
Aytu Bioscience Inc (AYTU) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Aytu Bioscience Inc (AYTU) closed the most recent trading day at $1.47, moving +1.38% from the previous trading session.
Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aytu Bioscience, Inc. (AYTU) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) closed at $1.64 in the latest trading session, marking a +1.23% move from the prior day.
What's in Store for Aytu BioScience's (AYTU) Q3 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.
Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
Aytu Bioscience, Inc. (AYTU) Stock Moves -1.27%: What You Should Know
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) closed at $1.55 in the latest trading session, marking a -1.27% move from the prior day.
Aytu Bioscience, Inc. (AYTU) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aytu Bioscience, Inc. (AYTU) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) closed at $1.52 in the latest trading session, marking a -1.3% move from the prior day.
Top Ranked Momentum Stocks to Buy for April 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd
Top Ranked Momentum Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 2nd
Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
Aytu BioScience (AYTU) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Aytu BioScience (AYTU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Aytu BioScience to Issue Coronavirus Rapid Test in North America
by Zacks Equity Research
Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.
Coronavirus Scare Supports These Biotech ETFs & Stocks
by Sanghamitra Saha
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
Coronavirus Test Kit Demand to Drive These 3 Stocks
by Zacks Equity Research
Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
Aytu BioScience, Inc. (AYTU) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aytu BioScience, Inc. (AYTU).
Wall Street Rises on Trump's Stimulus: ETF & Stock Gainers
by Sanghamitra Saha
Trump plans to offer fiscal stimulus to counter coronavirus-related economic fallout. As the Wall Street rallied on the hopes, these ETFs and stocks gained massively.
Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aytu Bioscience, Inc. (AYTU) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of -6.67% and -0.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.